BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price lowered by investment analysts at Morgan Stanley from $120.00 to $119.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s target price would indicate a potential upside of 120.24% from the stock’s current price.
Several other research firms have also issued reports on BMRN. Canaccord Genuity Group lifted their price target on shares of BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. HC Wainwright restated a “neutral” rating and issued a $55.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday. Bank of America decreased their price target on shares of BioMarin Pharmaceutical from $97.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Sanford C. Bernstein lifted their price target on shares of BioMarin Pharmaceutical from $90.00 to $94.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings upgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $90.86.
Read Our Latest Research Report on BMRN
BioMarin Pharmaceutical Price Performance
Insider Buying and Selling at BioMarin Pharmaceutical
In other news, EVP Charles Greg Guyer sold 16,486 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the sale, the executive vice president owned 79,953 shares of the company’s stock, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. This trade represents a 14.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.85% of the company’s stock.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Several institutional investors and hedge funds have recently modified their holdings of the stock. State of Michigan Retirement System grew its holdings in shares of BioMarin Pharmaceutical by 1.8% during the 1st quarter. State of Michigan Retirement System now owns 46,200 shares of the biotechnology company’s stock valued at $2,610,000 after acquiring an additional 800 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of BioMarin Pharmaceutical by 3.8% during the 1st quarter. Principal Financial Group Inc. now owns 428,607 shares of the biotechnology company’s stock valued at $24,212,000 after acquiring an additional 15,549 shares in the last quarter. Chicago Partners Investment Group LLC grew its holdings in shares of BioMarin Pharmaceutical by 2.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 290 shares in the last quarter. J. Safra Sarasin Holding AG grew its holdings in shares of BioMarin Pharmaceutical by 41.7% during the 1st quarter. J. Safra Sarasin Holding AG now owns 43,719 shares of the biotechnology company’s stock valued at $2,470,000 after acquiring an additional 12,859 shares in the last quarter. Finally, Citizens Financial Group Inc. RI purchased a new position in shares of BioMarin Pharmaceutical during the 1st quarter valued at $278,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.
More BioMarin Pharmaceutical News
Here are the key news stories impacting BioMarin Pharmaceutical this week:
- Positive Sentiment: Q1 revenue beat estimates and company raised full‑year revenue guidance to $3.825B–$3.925B, citing portfolio additions (GALAFOLD®, POMBILITI® + OPFOLDA®) as growth drivers — this supports longer‑term top‑line growth expectations. PR Newswire: BioMarin Reports First Quarter 2026 Financial and Operating Results
- Positive Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and set a $66 price target (~21% upside from current levels), which could provide analyst‑driven support if sentiment improves. TickerReport / Benzinga: RBC reaffirms rating, $66 PT
- Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $55 price target — little change to sell‑side consensus and a reminder of mixed analyst views. TickerReport / Benzinga: HC Wainwright reaffirmation
- Neutral Sentiment: Full Q1 earnings call transcript and slide deck are available for details on drivers and margin outlook; these materials may clarify management’s path to margin improvement. Seeking Alpha: Q1 2026 earnings call transcript
- Negative Sentiment: Q1 EPS of $0.76 missed the Zacks consensus of $0.94 and fell year‑over‑year, a clear near‑term earnings disappointment that weighs on valuation multiples. Zacks: Q1 earnings lag estimates
- Negative Sentiment: FY EPS guidance was set at $4.85–$5.05 vs. a Street consensus near $4.98 — a mild shortfall that, combined with the EPS miss, increases near‑term investor caution despite revenue upside. BioMarin Q1 press materials (slide deck / press release)
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
Read More
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
